Author

Shuozi Liu

Observed names: Shuo-Zi Liu, Shuo‐zi Liu

Institutions: Peking University, Peking University Third Hospital

Observed institutions: Peking University, Peking University Third Hospital

ORCID: 0000-0002-9033-9889

Observed ORCID: 0000-0002-9033-9889

OpenAlex ID: A5048630722

Real‐world treatment and outcome patterns of patients with mantle cell lymphoma in China: A large, multicenter retrospective analysis

2023 · Ping Yang, Qing‐qing Cai, et al. · Cancer Medicine · 17

PDF

Genomic landscape and distinct molecular subtypes of primary testicular lymphoma

2024 · Weilong Zhang, Ping Yang, et al. · Journal of Translational Medicine · 8

Genetic and prognostic analysis of blastoid and pleomorphic mantle cell lymphoma: a multicenter analysis in China

2024 · Ping Yang, Shuo-Zi Liu, et al. · Annals of Hematology · 4

Identification of six hub genes in mantle cell lymphoma patients with BTKi resistance

2022 · Shuozi Liu, Ping Yang, et al. · Annals of Translational Medicine · 4

PDF

Prognostic role of interim PET-CT demonstrating partial metabolic response in diffuse large B-Cell lymphoma: a retrospective study

2025 · Jinjie Gao, Shuozi Liu, et al. · Annals of Hematology · 3

PDF

Treatment outcomes of BTK inhibitors and venetoclax with or without anti-CD20 monoclonal antibody in relapsed or refractory mantle cell lymphoma

2025 · Ping Yang, Chun-Yuan Li, et al. · Annals of Hematology · 3

PDF

Development of a new risk scoring system based on spleen involvement and the lymphocyte/monocyte ratio for follicular lymphoma patients

2022 · Chunyuan Li, Wei Zhang, et al. · Leukemia Research · 3

Inhibition of CDC20 suppresses the development and progression of mantle cell lymphoma through PI3K/AKT pathway

2026 · Yingtong Chen, Ping Yang, et al. · Annals of Hematology · 2

PDF

TP53 mutation heterogeneity reveals distinct prognoses in mantle cell lymphoma

2026 · Shuozi Liu, Shaowei Zhou, et al. · Annals of Hematology · 2

PDF

Clinical outcomes and therapeutic modalities in older Chinese patients with MCL: a multi-center real-world retrospective study

2025 · Yuan Yang, Ping Yang, et al. · Annals of Medicine · 2

2021 · Jun-Yu Li, Shuo-Zi Liu, et al. · World Journal of Clinical Cases · 2

Genetic and Prognostic Analysis in Blastoid and Pleomorphic Mantle Cell Lymphoma: A Multicenter Analysis in China

2022 · Ping Yang, Shuozi Liu, et al. · Blood · 1

Prognostic impact of monocyte percentage and extranodal involvement in classical hodgkin lymphoma: A multicenter real-world study of 547 chinese patients

2026 · Lingli Wang, Jinping Pi, et al. · Annals of Hematology

PDF

Efficacy and safety of zanubrutinib combined with age-adapted bendamustine and rituximab followed by zanubrutinib maintenance therapy in elderly patients with mantle cell lymphoma: a retrospective analysis

2026 · Xiaoyu Hao, Jiabin Zhang, et al. · Leukemia & lymphoma/Leukemia and lymphoma

PDF

Current progress of CDC20 in cancer development and targeting CDC20 for cancer therapy

2026 · Yingtong Chen, Shuang Gao, et al. · Carcinogenesis

Efficacy and safety of zanubrutinib combined with reduced-dose bendamustine and Rituximab for eldly Mantle Cell Lymphoma: A retrospective analysis

2025 · Ping Yang, Shuozi Liu, et al. · Blood

Heterogeneous TP53 mutation subtypes define prognostic classification in Mantle Cell Lymphoma

2025 · Shuozi Liu, Ping Yang, et al. · Blood

PDF

Is autologous hematopoietic stem cell transplantation as consolidation therapy superior to chemotherapy alone in newly diagnosed intermediate-high risk DLBCL patients?

2025 · Shuozi Liu, Lan Ma, et al. · Blood

Prognostic impact of central nervous system prophylaxis and a simplified BL model in primary testicular lymphoma: a real-world multicenter study

2025 · Shuozi Liu, Ping Yang, et al. · Journal of Cancer Research and Clinical Oncology

PDF

Treatment Outcomes of BTK Inhibitors and Venetoclax with/without Anti-CD20 Monoclonal Antibody in Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Real-World Experience